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tivity analysis was conducted and conﬁrmed the robustness of the
results. CONCLUSIONS: Findings suggest XELOX as a cost-
saving therapy for the ﬁrst line treatment for mCRC under the
payer perspective in Brazil when compared to FOLFOX-6. when
compared to FOLFOX-6.
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OBJECTIVES: to compare the costs of maintenance therapy with
currently used preparations for hormone-sensitive prostate
cancer with a new leuprorelin 6-month depot (L6) preparation.
METHODS: Patient data were extracted from the IMS Disease
Analyzer observational database. UK patients with a diagnosis of
prostate cancer and three or more prescriptions for goserelin or
leuprorelin were eligible. Individual prescription events were
included if they were for goserelin 28-day depot (G28) or
12-week depot (G84) or for leuprorelin one month or 3-month
depots (L1 and L3). Total cost included drug cost, physician and
nurse visits, prostate speciﬁc antigen (PSA) testing, and payments
for implant administration. The cost of treatment with a newly
available L6 was estimated by varying the daily drug cost, and
assuming resource use equivalent to L3. RESULTS: 118 patients
reported 1262 prescriptions for L3 compared to 600 patients
(8433 prescriptions) for G84, 36 patients (489 prescriptions) for
L1 and 272 patients (2984 prescriptions) for G28. A separate
visit for implant administration was required for 35% of pre-
scriptions with L3, 29% with L1, 41% with G84 and 28% with
G28. PSA testing, although recommended in the UK, occurred
infrequently around the time of prescription (5% of events). The
cost per patient of one year of treatment was £1656 with L3,
£1507 (G84), £1949 (L1) and £2121 (G28). The cost of one year
treatment with L6 if based on the daily drug cost of L3, would be
£1580. Applying the daily drug cost of G28 resulted in £1169,
while applying the G84 daily cost increased it to £1235. Patient
drug costs ranged from 52% of the total cost (G28) to 95% (L6).
CONCLUSIONS: The cost of maintenance therapy for hormone
sensitive prostate cancer is lower when longer-acting prepara-
tions are given, due principally to reductions in non-drug cost
such as GP visit costs.
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OBJECTIVES: To asses the pharmacoeconomic evaluation of
erlotinib used in the second line treatment of metastatic and
developed locoregional non-small lung cancer in the conditions
of the Czech reimbursement policy. We compared costs of
tyrosine-kinase inhibitor erlotinib with the other cytostatic
agents docetaxel and pemetrexed recommended according to
Czech oncological guidelines. METHODS: In the absence of
head to head studies we used data based on clinical trials com-
paring docetaxel and pemetrexed (JMEI) and BR21 study com-
paring erlotinib and placebo. We conducted cost-minimization
analysis from the perspective of the payer. We calculated costs
of drugs, administration, monitoring, premedication, transport
of patients and managment the hematologic toxicities. Prices of
drugs were based on the list of reimbursement of drugs provided
by an reimbursement agency (State Institute for Drug Control)
and payments for health intervencies were collected from the
prices of health care published by health insurance companies.
RESULTS: The costs were calculated for four terapeutic cycles
which referred to median number of cycles administered in the
clinical trials and it was in a concordance with the median value
of progression-free survival. The total costs associated with
therapy were €207,238, €131,720 and €320,000 CZK (€8,635,
€5,488 and €13 333) for erlotinib, docetaxel and pemetrexed.
The acquisition cost was 310,720 CZK (€12,429) for pemetr-
exed, 206,565 CZK (€8,263) for erlotinib and 104,832 (€4,193)
for docetaxel. Erlotinib has more favourable tolerability proﬁle
whereas the cost of adverse events in docetaxel arm was 23,388
CZK (€936) and in pemetrexed arm 5,969 CZK (€239). Also the
administration, monitoring and transportation costs of erlotinib
was signiﬁcantly lower than for docetaxel and pemetrexed.
CONCLUSIONS: The less costly alternative in second-line
therapy of metastatic non-small lung cancer was docetaxel
because of lowest acquisition price. Erlotinib has lowest toxicity,
administration and transportation cost. The cost of erlotinib
is partly compensated by the reduction of toxicity and
management/administration costs.
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OBJECTIVES: Current technology does not adequately predict
the prognosis of patients with acute myeloid leukaemia (AML).
Many patients therefore undergo unneeded but costly and toxic
treatment. However, innovative approaches using genomics,
epigenomics and proteomics technology are being developed to
ameliorate this problem. The aim of this study was to estimate
the potential economic and health impact of these technologies
for AML. METHODS: This study was based on a literature
review and expert opinion regarding the epidemiology, clinical
practice and costs relating to AML and its treatment. Data were
subsequently analysed using decision modelling. RESULTS: Con-
ventional methods help to divide patients into three categories:
favourable prognosis (20% of patients, >60% chance of sur-
vival); intermediate prognosis (60%, 30–40%); and poor prog-
nosis (20%, <20%). Improved diagnostics would reduce the
frequency and costs of unneeded treatment (chemotherapy, stem
cell transplantation). Speciﬁcally, it could reassign some interme-
diate prognosis patients to the favourable prognosis category
(approx. 10%) and others to the poor prognosis category
(approx. 20%). Cost-savings could be €10,000–15,000 per
patient assuming average costs of €100,000. Avoidance of unnec-
essary therapy would also reduce frequencies of side-effects.
While better diagnostics would also result in some extra costs
because of treating patients more intensively, these treatments
would also lead to health gain. Given current diagnostic costs of
€1500–5000 per patient and the high volume of tests, the cost
reduction achievable by improving AML diagnostics would save
millions of euros per year. CONCLUSIONS: Improved AML
diagnostics would reduce some diagnosis, prognosis, and treat-
ment costs. Any increased treatment costs would be coupled with
health gain. In addition, rapid testing would reduce the time
needed to develop a treatment plan and may thereby improve
prognosis.
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